Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Annie Guérin
Debbie Goldschmidt
Tania Small
Patrick Gagnon-Sanschagrin
Hela Romdhani
Genevieve Gauthier
Sneha Kelkar
Eric Q. Wu
Polly Niravath
Anand A. Dalal
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
[5] Novartis Pharmaceuticals Corporation,undefined
[6] Analysis Group,undefined
[7] Inc.,undefined
[8] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
CDK4/6 inhibitor; HR+/HER2−; Metastatic breast cancer; Monitoring; Oncology; Post-menopausal;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1264
页数：13
相关论文
共 50 条
  • [41] Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: A chart review study in the US
    Xie J.
    Hao Y.
    Li N.
    Lin P.L.
    Ohashi E.
    Koo V.
    Wu E.Q.
    Experimental Hematology & Oncology, 4 (1)
  • [42] Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer
    Matthew Loft
    Sheau Wen Lok
    Richard De Boer
    Laeeq Malik
    Sally Greenberg
    Belinda Yeo
    Angelyn Anton
    Michelle Nottage
    Vanessa Wong
    Louise Nott
    Ian M. Collins
    Javier Torres
    Frances Barnett
    Janine M. Lombard
    Peter Gibbs
    Lucy Gately
    Breast Cancer Research and Treatment, 2023, 198 : 67 - 74
  • [43] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12) : 3131 - 3141
  • [44] Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
    Rossi, Lorenzo
    McCartney, Amelia
    Risi, Emanuela
    Malorni, Luca
    Biganzoli, Laura
    Di Leo, Angelo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [45] Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
    Wood, Robert
    Mitra, Debanjali
    de Courcy, Jonathan
    Iyer, Shrividya
    CLINICAL THERAPEUTICS, 2017, 39 (08) : 1719 - 1728
  • [46] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [47] Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer
    Yuko Nakayama
    Hiroshi Nakagomi
    Masato Omori
    Masayuki Inoue
    Kazunori Takahashi
    Masahiro Maruyama
    Atsushi Takano
    Kazushige Furuya
    Kenji Amemiya
    Eri Ishii
    Toshio Oyama
    Breast Cancer, 2016, 23 : 633 - 639
  • [48] Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer
    Nakayama, Yuko
    Nakagomi, Hiroshi
    Omori, Masato
    Inoue, Masayuki
    Takahashi, Kazunori
    Maruyama, Masahiro
    Takano, Atsushi
    Furuya, Kazushige
    Amemiya, Kenji
    Ishii, Eri
    Oyama, Toshio
    BREAST CANCER, 2016, 23 (04) : 633 - 639
  • [49] CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2-metastatic breast cancer
    Dent, Susan
    Guha, Avirup
    Moore, Heather
    Makari, Doris
    Mccaleb, Rachael
    Arias, Irene
    Stergiopoulos, Stella
    Li, Benjamin
    Fradley, Michael
    CARDIO-ONCOLOGY, 2025, 11 (01)
  • [50] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Amar, Surabhi
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) : 1 - 7
12345